Stoke Therapeutics (STOK)

• Market cap: $1.82B
• 1 day: -2.43%
• 5 days: 0%
• 1 month: 0.83%
• 3 months: -13.81%
• 6 months: -12.91%
• Year to date: -5.28%
• 1 year: 150.17%
• 5 years: -20.33%
• 10 years: 14.47%
• Sector: Healthcare
• Industry: Biotechnology

About: Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Employees: 170